文献速递肺结节与肺癌

EGFR野生型晚期NSCLC二线治疗:EGFR-TKI与化疗的真实世界比较

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
PubMed 文献 · Eur Respir J · 2017-08-10

基于法国Biomarkers France队列中1278例EGFR野生型晚期NSCLC患者,比较二线EGFR-TKI与化疗的疗效。化疗组总生存和无进展生存均优于EGFR-TKI组,提示在免疫治疗时代三线治疗应优先选择化疗而非EGFR-TKI。

要点

  • EGFR野生型NSCLC二线化疗的总生存优于EGFR-TKI(8.38 vs 4.99个月)。
  • 二线化疗的无进展生存也优于EGFR-TKI(4.30 vs 2.83个月)。
  • 三线治疗应优先选择化疗而非EGFR-TKI。

核心结论

  • 在EGFR野生型晚期NSCLC患者中,二线化疗的总生存和无进展生存均优于EGFR-TKI。
  • 免疫治疗已获批二线治疗的背景下,三线治疗应优先选择化疗而非EGFR-TKI。

研究设计与样本

  • 基于法国Biomarkers France全国性队列,纳入1278例接受二线治疗的EGFR野生型NSCLC患者。
  • 868例接受化疗,410例接受EGFR-TKI,收集临床、生物学、治疗和结局数据。

主要发现

  • 化疗组中位总生存为8.38个月,EGFR-TKI组为4.99个月(HR 0.70,95%CI 0.59-0.83;p<0.0001)。
  • 化疗组中位无进展生存为4.30个月,EGFR-TKI组为2.83个月(HR 0.66,95%CI 0.57-0.77;p<0.0001)。

临床怎么用

  • EGFR野生型晚期NSCLC二线治疗应优先选择化疗而非EGFR-TKI。
  • 三线治疗决策中,化疗的总生存和无进展生存优于EGFR-TKI,应优先考虑化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of EGFR wild-type (EGFR-wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era of immunotherapy, many drugs are approved for second-line treatment of EGFR-wt NSCLC and there is a need to reassess the role of EGFR-TKIs in this setting.The Biomarkers France study is a large nationwide cohort of NSCLC patients tested for EGFR mutations. We used this database to collect clinical, biological, treatment and outcome data on EGFR-wt patients who received second-line treatment with either EGFR-TKIs or chemotherapy.Among 1278 patients, 868 received chemotherapy and 410 received an EGFR-TKI. Median overall survival and progression-free survival were longer with chemotherapy than with an EGFR-TKI. Overall survival was 8.38 versus 4.99 months, respectively (hazard ratio 0.70, 95% CI 0.59-0.83; p<0.0001) and progression-free survival was 4.30 versus 2.83 months, respectively (hazard ratio 0.66, 95% CI 0.57-0.77; p<0.0001).This study is helpful to guide a multiline treatment strategy for EGFR-wt NSCLC patients. Immunotherapy is approved for second-line treatment. For third-line treatment, chemotherapy results in longer overall survival and progression-free survival, and should be preferred to EGFR-TKIs.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Tomasini P, Brosseau S, Mazières J, et al. EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. Eur Respir J. 2017. PMID: 28798090. doi:10.1183/13993003.00514-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。